Summary Immunotoxins that carry two toxin molecules to the target cell should in theory have a greater anti-tumour effect than those that carry just one. We have investigated the therapeutic efficacy of two anti-CD7-saporin immunotoxins constructed with one saporin (HB2-Sap 1 -mer) or two saporin molecules (HB2-Sap 2-mer) per immunotoxin molecule. In vitro, the 2-mer immunotoxin was 5.6 times more effective than the 1 -mer immunotoxin at inhibiting protein synthesis in the CD7+ human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HSB-2 and was also more effective at inhibiting HSB-2 cell proliferation. Flow cytometry revealed that the 2-mer immunotoxin had a reduced binding capacity to HSB-2 cells compared with the 1-mer immunotoxin or native HB2 antibody. In therapy studies in SCID mice with disseminated HSB-2 human leukaemia, the 2-mer immunotoxin performed marginally better than the 1-mer immunotoxin, but log-rank analysis did not reveal any significant differences between the two therapy groups. We therefore conclude that, although the 2-mer immunotoxin performed better than the 1 -mer immunotoxin against target HSB-2 cells in vitro, this improved performance was not reflected as an improved in vivo therapeutic outcome in the SCID mouse model.
Immunotoxins (ITs) have promising potential as therapeutic agents for cancer, particularly in the treatment of leukaemias and lymphomas, in which they have been shown to have marked activities Falini et al, 1992 ; Amlot et al, 1993; Grossbard et al, 1993) . Comprising a monoclonal antibody component linked to a toxin or ribosome-inactivating protein (rip), such as ricin A chain or saporin, immunotoxins selectively deliver the toxin moiety only to cell populations expressing the target antigen recognized by the antibody. There are, however, a multitude of factors that can effect the potency of a given immunotoxin for its target cell, which can severely limit its therapeutic value. At the mechanistic level, such factors include the isotype and affinity (van-Oosterhout et al, 1994) of the antibody component, the proximity of the target antigen epitope to the target cell membrane (Press et al, 1988 , the expression by the target cell of antigens unrelated to the target antigen and that probably assist in the internalization of immunotoxin by receptor-mediated endocytosis (van-Oosterhout et al, 1994) and, of pivotal importance, the fundamental nature of the target antigen and the ease with which it internalizes to the appropriate intracellular compartment once antibody has bound to its target ligand , Preijers 1988 , Wargalla and Reisfeld 1989 . Ultimately, the key determinants governing the therapeutic potency of any given immunotoxin revolve around two key issues: firstly, the in vivo accessibility of immunotoxin to the tumour and, secondly, the efficiency of the internalization and trafficking process which delivers immunotoxin to the appropriate intracellular compartment. The toxin component is then able to catalytically inactivate cellular ribosome activity, leading ultimately to cell death.
Any method that improves immunotoxin potency without a concomitant increase in toxicity would be a step forward in the goal to achieve a better therapeutic index with this class of pharmaceutical. We have recently shown that the use of a combination of two different immunotoxins, each immunotoxin (IT) recognizing a different target molecule (CD19 and CD38) on the surface of the Burkitt's lymphoma cell line Ramos, leads to a significantly better therapeutic outcome in SCID mice than that obtained when each IT is used individually (Flavell et al, 1995a) . We speculate that this improvement is due to two main factors; firstly, lymphoma cells positive for both CD19 and CD38 would receive more saporin when both molecules are simultaneously targeted; and, secondly, cells that were negative or down-regulated for one of the target molecules and would otherwise escape killing by a single IT recognizing this antigen would be killed by the other IT in the combination. Increasing the number of saporin molecules delivered to the target cell by any individual IT would thus be one possible route to increasing immunotoxin potency. One way of achieving this would be to conjugate more toxin moieties per single unit of antibody. In the current study, we have compared the in vitro and in vivo therapeutic efficacy of anti-CD7 HB2-Sap ITs constructed with one (1 -mer) or two (2-mer) saporin molecules per antibody molecule. We show that, while the in vitro potency of the 2-mer IT is substantially greater than the 1-mer IT, the in vivo performance of the two ITs in SCID mice bearing HSB-2 leukaemia is similar. However, the toxicity of the 2-mer IT is substantially increased.
MATERIALS AND METHODS SCID mice
Pathogen-free CB-17 scid/scid (SCID) mice of both sexes (6-10 weeks of age) were produced from our own breeding colony and used in all the experimental work described here. The breeding colony is maintained to British Home Office requirements under sterile conditions inside a laminar flow isolator, and animals are housed on sterile bedding and provided with sterile water and food ad libitum. Animals for experimental use were transferred from the isolator to autoclaved filter-top microisolator cages and housed on sterile bedding as five single sex animals per cage. These animals were also provided with sterile water and food ad libitum, and all manipulations with these animals were carried out in a laminar flow hood by personnel using aseptic techniques.
HSB-2 human T-AII cell line
The CD7+ human cell line HSB-2 was originally established from peripheral blood leukaemic blasts from a 4-year-old paediatric patient with terminal T-cell acute lymphoblastic leukaemia (Adams et al, 1970) . HSB-2 cells were maintained in the logarithmic phase of growth in culture flasks containing antibiotic-free RPMI medium with 10% fetal calf serum and supplements of 2 aM sodium pyruvate and 2 mm glutamine (referred to as RIO medium) at 37°C under a humidified atmosphere of 5% carbon dioxide.
HB2 anti-CD7 antibody production
The anti-CD7 antibody-producing hybridoma clone HB2 was obtained from the American Tissue Culture Collection (ATCC, Bethesda, MD, USA). Bulk anti-CD7 antibody was produced by inoculating 5 x 108 HB2 hybridoma cells into an Endotronics Accusyst R hollow fibre bioreactor (Endotronics, MN, USA), as per manufacturers instructions with some minor modifications. Harvested antibody-containing culture supematants were concentrated on a Sartorius cross-flow filtration apparatus equipped with a 30 000 kDa cut-off sanitizable cellulose acetate membrane. HB2 antibody was purified to homogeneity from culture supernatants by a combination of ammonium sulphate precipitation, anion-exchange chromatography on DEAE-Sepharose (Sigma Chemical, Poole, UK) and Sephacryl-S200HR (Sigma Chemical) gel filtration. Saporin production Seeds of the Soapwort plant Saponaria officinalis were kindly supplied by Chiltern Seeds, Ulverston, Cumbria, UK. The S06 isoform of saporin was extracted from seeds as described previously (Stirpe et al, 1983 ) and purified to homogeneity by a combination of cation-exchange chromatography on carboxymethyl-Sepharose and gel filtration on Sephacryl-S200HR. The final product gave a single band of 29 500 Da on SDS-PAGE and was immunoreactive on ELISA with both polyclonal and monoclonal anti-saporin antisera.
Construction of 1-mer and 2-mer HB2-Sap immunotoxins Saporin was coupled to intact HB2 antibody using the heterobifunctional cross-linking agent N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), as described previously (Thorpe et al, 1985) . The immunotoxin HB2-Sap produced by this procedure comprises a mixture of free HB2 antibody; 1-mer IT comprised one saporin molecule per antibody molecule and 2-mer IT comprised two saporin molecules per antibody molecule and a trace amount of 3-mer IT. Each of these components were separated from each other by carboxymethyl-Sepharose cation-exchange chromatography in 5 mm phosphate buffer (pH 6.5), as described previously (Lambert et al, 1983 ) but using a custom-designed and optimized semi-stepwise linear elution gradient of sodium chloride. Briefly, the bulk of the free HB2 antibody was eluted from the column with a linear gradient of 60-80 mm sodium chloride; the 1-mer IT was eluted between 80 and 105 mm and the 2-mer IT as a single peak between 105 and 180 mm (see Figure 1) . The l-mer and 2-mer ITs obtained were dialysed into phosphate-buffered saline (PBS) (pH 7.2) and filter sterilized by passage through a 0.2-mm pyrogen-free filter. Concentrations of the individual immunotoxin species were estimated spectrophotometrically at 280 nm and reported as total protein content expressed as a molar concentration, without taking into account any contaminating species.
Sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) analysis of 1-mer and 2-mer immunotoxins 300 SDS-PAGE analysis, according to the method of Laemmli (1970) 
Protein synthesis inhibition assay
The ability of HB2-Sap 1-mer or 2-mer immunotoxins to inhibit protein synthesis in the HSB-2 target cell line was evaluated using a [3H]leucine uptake assay described by us previously (Flavell et al, 1991) . Briefly, triplicate cultures of 1 x 105 target HSB-2 cells were exposed to individual equimolar concentrations of each IT or saporin in RIO medium and incubated at 370C for 48 h in a humidified atmosphere of 5% carbon dioxide 95% air. After this period of time, 1 ,uCi of [3H]leucine was added to each culture and incubation continued for a further 14-16 h. Cells were harvested onto glass fibre discs using a Skatron cell harvester, and individual discs were counted for radioactivity on a Packard scintillation counter.
In experiments undertaken to quantify the amount of native HB2 antibody required to block the cytotoxicity of 1-mer and 2-mer ITs, triplicate cultures of 1 x 105 HSB-2 cells were exposed for 48 h to a fixed 0.1 nm concentration of the 1-mer or 2-mer IT together with increasing molar concentrations of native HB2 antibody and processed exactly as described above.
For kinetic studies, triplicate cultures of HSB-2 cells were exposed to five different molar concentrations of 1-mer or 2-mer IT (1 pM-I0 nM) or saporin (10 nM-I mM) for 2, 6, 10, 24 and 48 h. Cultures were pulsed with 1 pCi [3H]leucine for 2 h before harvest onto glass fibre discs for counting, exactly as described above.
HSB-2 cell outgrowth assay
The effects of four different molar concentrations (5.28 pM, 52.8 pM, 0.528 nM and 5.28 nM) of the 1-mer and 2-mer IT on HSB-2 cell proliferation in vitro was investigated. Approximately 105 HSB-2 cells were cultured in RIO medium in T25 culture flasks in the continuous presence of a given molar concentration of IT. Control cultures were grown in RIO medium only. Viable cell counts were evaluated on a haemocytometer using trypan blue exclusion at regular intervals.
HSB-2 human T-cell leukaemia in SCID mice
The behaviour and characteristics of the human T-cell acute lymphoblastic leukaemia cell line HSB-2 in SCID mice has been described previously (Morland et al, 1994) . In the present study,
Pharmacokinetics of 1-mer and 2-mer immunotoxins in SCID mice
Two SCID mice, injected into the tail vein 7 days previously with 2 x 106 HSB-2 cells, received 50 .tg of either 1-mer or 2-mer IT in PBS as a single bolus tail vein injection in a total volume of 100 xl. Approximately 50 p1 of blood was taken from the tail before injection with IT and 10 min, 1, 2, 4, 6, 8, 11, 24, 32 and 48 h after injection. Blood was allowed to clot at room temperature, and serum was separated by centrifugation and stored at -80°C until assayed. IT concentrations in serum samples were quantified using a sensitive capture-type enzyme-linked immunosorbent assay (ELISA). Figure 1 shows the elution profile of HB2-Sap 1-mer and 2-mer ITs from CM-sepharose using a discontinuous linear gradient of sodium chloride ranging from 0 to 300 mm. Fractions from three regions of the elution peaks as indicated (I to III) were pooled and subjected to non-reducing SDS-PAGE analysis, the results of which are shown in Figure 2 . Image analysis of detected bands revealed that lane 1 (containing fractions comprising region II) was composed of 84% 1-mer IT with molecular weight (MW) of 189.5 kDa, 12% free HB2 antibody (MW 160 kDa) and 4% contaminating 2-mer IT. Lane 2 (region III) contained approximately 92% 2-mer IT (MW 219 kDa), 5% contaminating 1-mer IT and 3% free HB2 antibody; while lane 3 (region I) contained >99% native HB2 antibody with no detectable contaminating IT.
Binding of 1-mer and 2-mer HB2-Sap immunotoxins to HSB-2 cells
The binding of three equimolar concentrations of 1 -mer and 2-mer HB2-Sap ITs and native HB2 antibody to HSB-2 leukaemia cells was measured by flow cytometry and the mean fluorescent intensity of staining obtained for each is presented in Table 1 . The 1-mer IT showed staining characteristics similar to those of native HB2 antibody at all three equimolar concentrations studied. The 2-mer IT, however, showed an overall reduced binding capacity for HSB-2 cells, particularly pronounced at the subsaturating concentration of 6.25 x 10-9 M for which the mean fluorescent intensity obtained with 2-mer IT was only approximately half that seen with native HB2 antibody. To establish that this reduced binding capacity of the 2-mer IT was due to an effect on the antigen binding site and not on the binding capacity of the FITC-labelled secondary reagent, we conducted a competitive inhibition experiment, and the results we obtained are shown in Figure 3 . The results clearly show that the 1-mer IT competed with native HB2 antibody more effectively than the 2-mer, demonstrating unequivocally that the 1-mer IT had a higher binding affinity for CD7 on the surface of the HSB-2 cell. This indicates that the reduced fluorescent intensity observed for the 2-mer IT in the indirect fluorescent assay was indeed due to an effect on the antigen binding site.
Protein synthesis inhibition in HSB-2 cells by 1-mer and 2-mer immunotoxins
The dose-dependent effects of 1-mer and 2-mer HB2-Sap ITs on protein synthesis levels in HSB-2 leukaemia cells are shown in in Figure SD . The data presented in Figure 5D show that the 2-mer Blocking of 1-mer and 2-mer immunotoxin protein synthesis inhibitory activity for HSB-2 cells by HB2 antibody antibody plus saporin at a 1 -mer equivalent ratio (----) or (E) PBS sham treated (-) synthesis inhibition to half that seen in untreated controls (IC50), the 2-mer IT required 3.7 times more antibody (1.1 x 10-8 M) than the 1-mer IT (3 x 10-9 M) to achieve the same effect ( Figure 6 ). Total blockade of both 1-mer IT-and 2-mer IT-mediated cytotoxicity was only achieved at a gross excess antibody concentration of 10-7 M. Each IT was present in the assay system at a fixed concentration of 1 x 10-10 M, and we can therefore conclude that a 1000-fold molar excess of native HB2 antibody is required to completely block IT cytotoxicity. Native HB2 antibody alone, used over the same concentration range but without IT, had no effect on protein synthesis levels ( Figure 6 ).
Effects of HB2-Sap 1-mer and 2-mer ITs on HSB-2 cell proliferation
The effects of four different equimolar concentrations of 1-mer or 2-mer IT on HSB-2 cell proliferation in vitro are shown in Figure  7 . The 2-mer IT was more effective at inhibiting HSB-2 cell proliferation than the 1-mer IT, delaying cell growth by several days.
Used over the same concentration range, neither I T had any effect on the growth of the CD7-cell line NALM-6 (data not shown).
Pharmacokinetic profiles of 1-mer and 2-mer immunotoxins
A two-compartment first-order pharmacokinetic model was used to fit the 1-mer and 2-mer IT serum concentration data. The pharmacokinetic parameters obtained for both the 1 -mer and 2-mer ITs in HSB-2 tumour-bearing SCID mice are shown in Table 2 . It was apparent that there was a very marked increase in the tl,2 (a) and t 12 (,3) phases for the 2-IT and a resultant larger AUC for the 2-mer IT.
Toxicity of 1-mer and 2-mer ITs in SCID mice Figure 9 , and the data is summarized in at the termination of the experiment. Treatment with native HB2 antibody plus saporin at two different ratios equivalent in molar terms to 1-mer and 2-mer IT did have a therapeutic effect, increasing mean survival to 83.8 and 88.7 days, respectively, with only one animal from these groups surviving disease-free for the duration of the study. Log-rank analysis revealed that the differences between the PBS sham-treated group and 1-mer IT-and 2-mer IT-treated groups were highly significant (P=0.0316 and P=0.0071 respectively). However, the difference between the 1-mer and 2-mer IT therapy groups was not significant (P=0.6306). The improved survival seen when a mixture of native HB2 antibody plus saporin was used at an equivalent 1-mer (but not 2-mer) molar ratio was just significant when compared with sham-treated controls (P=0.0573). and that a proportionatly greater excess of native HB2 antibody was required to block the cytotoxic activity of the 2-mer than was required for the 1-mer IT. Similarly, other workers have described similar increases in in vitro potency of ITs containing two toxin molecules per unit antibody (Marsh and Neville, 1986; (Fishwild et al, 1992; Jansen et al, 1992; Flavell et al, 1995a; Morland et al, 1994) (Dorshkind et al, 1985) (1997) 75(7), [1035] [1036] [1037] [1038] [1039] [1040] [1041] [1042] [1043] In order to determine the differential contribution that such diverse cytotoxic mechanisms contribute to the eventual therapeutic outcome, we are currently undertaking studies in NOD-SCID mice, which are naturally deficient in NK cells.
The present study addressed the question of both in vitro and in vivo immunotoxin potency in the context of the number of toxin molecules carried by a single antibody molecule to a single antigen unit on the target cell surface. The improved in vitro performance of the 2-mer IT over the l-mer IT, despite the reduced binding capacity of the 2-mer IT, is probably due to the delivery of twice the number of saporin molecules per unit target antigen and their resultant internalization by receptor-mediated endocytosis to the appropriate intracellular compartment, as discussed earlier. In addition to the 2-mer IT showing a demonstrably improved IC50 over the 1-mer IT, kinetic studies also revealed that the 2-mer IT inactivated protein synthesis in target HSB-2 cells more rapidly than the 1-mer IT. We have described a similar phenomenon previously with a combination of two bispecific antibodies delivering saporin to HSB-2 cells via CD7 and CD38 target molecules, resulting in a more rapid inactivation of protein synthesis (Flavell et al, 1992) . Although unproven, the most likely explanation for this would seem to be that increasing the overall number of toxin molecules delivered to and subsequently internalized by the target cell would increase the resultant probability of achieving a 'hit' on the target ribosome.
The finding that the increased in vitro potency of 2-mer IT over 1-mer IT did not translate into an improved in vivo therapeutic outcome in the SCID mouse model was disappointing. The 2-mer IT was considerably more toxic in the SCID mouse than the 1-mer IT, an observation that may possibly be explained by the greater serum half-life of 2-mer IT. Myers et al (1995) have made similar observations with an anti-CD19 immunotoxin (B43-PAP) in a SCID mouse model of human cALL and were also able in this instance to demonstrate that the IT species containing two PAP molecules was significantly more effective therapeutically than the single toxin-containing species. Ghetie et al (1995) undertook studies based upon one of our earlier reports (Flavell et al, 1995b) and showed that an anti-CD19 immunotoxin containing two ricin A chain toxin molecules per antibody molecule was more potent at inactivating protein synthesis in target cell lines in vitro than an equivalent IT containing just a single toxin molecule. However, there was little difference between the therapeutic performance of the one and two ricin A chain-containing ITs in a SCID-Daudi mouse model of human lymphoma. An anti-CD25 IT containing one or two ricin A-chain molecules performed almost identically both in vitro and in vivo. In contrast, an anti-CD22 IT containing two ricin A chain molecules per antibody molecule performed significantly better than an equivalent single toxin containing IT not only in vitro but also in vivo in the same SCID-Daudi model. In sharp contrast to our own findings, these workers report that all three of their two toxin-containing ITs were no more toxic in the mouse than the one toxin-containing ITs. The reasons for this are not clear, but it may reflect the greater sensitivity of the mouse to the hepatic and renal toxicity of saporin. It seems entirely possible that the properties and nature of the target molecule dictate the therapeutic potency of a given IT directed against this target. However, this alone cannot account for the disparities that appear to exist between in vitro and in vivo IT performance. Other issues, such as IT clearance rates from the blood, accessibility of target cells by the IT and heterogeneity of target antigen expression (Flavell et al, 1995a) by the target cells, are equally important factors that may have a profound influence on in vivo therapeutic efficacy. In the present study, the lack of improvement may relate to in vivo tumour accessibility, which may be reduced for the 2-mer IT because of its larger molecular size. The 2-mer IT, although more than 5 times more potent in vitro, also has a demonstrably lower in vivo therapeutic index because of its increased toxicity in the SCID mouse. While it was possible to administer three 10-p.g doses of the 1-mer IT to SCID mice without any attendant toxicity, we were only able to give a single 10-[tg dose of the 2-mer IT. This increased toxicity is almost certainly due to the increased serum half-life of the 2-mer IT and the resultant larger AUC. Ghetie et al (1995) , who did not find any increased toxicity in their two ricin A chain-containing ITs, did not provide any pharmacokinetic data on these ITs, and it is therefore not possible to comment on possible reasons for this in relation to our own findings. We thus conclude that there would appear to be no therapeutic advantage to be gained, at least in the presently described SCID model of human T-ALL, in constructing ITs with more than one saporin molecule linked to a single antibody molecule; indeed, the increased toxicity that is observed is a major disadvantage. However, the results of others suggest that different target molecules and different antibodies directed against the same target molecule may behave differently. To this end, we are currently exploring the in vivo therapeutic prformance of other 1-mer and 2-mer ITs constructed with different anti-CD7, -CDl9, -CD22 and -CD38 antibodies, each with different epitope specificities.
